2023 Q3 Form 10-Q Financial Statement

#000141057823001688 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $779.7K $2.917M
YoY Change -78.09% -32.1%
Cost Of Revenue $700.7K $1.648M
YoY Change -77.7% -49.4%
Gross Profit $79.00K $1.269M
YoY Change -81.04% 22.14%
Gross Profit Margin 10.13% 43.51%
Selling, General & Admin $3.311M $3.292M
YoY Change -14.52% 9.23%
% of Gross Profit 4191.03% 259.38%
Research & Development $938.9K $836.1K
YoY Change 2.85% -3.12%
% of Gross Profit 1188.49% 65.87%
Depreciation & Amortization $332.2K $349.1K
YoY Change 1.39% 8.71%
% of Gross Profit 420.57% 27.51%
Operating Expenses $4.250M $4.128M
YoY Change -11.21% 6.49%
Operating Profit -$4.171M -$2.859M
YoY Change -4.55% 0.75%
Interest Expense $41.22K $26.78K
YoY Change 2865.47%
% of Operating Profit
Other Income/Expense, Net $514.0K -$3.469K
YoY Change -86.12% -92.34%
Pretax Income -$3.616M -$3.114M
YoY Change 444.07% 176.87%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.592M -$3.100M
YoY Change 441.64% 175.73%
Net Earnings / Revenue -460.7% -106.25%
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.26 -$0.24
COMMON SHARES
Basic Shares Outstanding 13.66M 12.91M
Diluted Shares Outstanding 12.91M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.152M $10.76M
YoY Change -53.0% 129.74%
Cash & Equivalents $7.152M $10.76M
Short-Term Investments
Other Short-Term Assets $389.2K $524.9K
YoY Change -63.21% -5.36%
Inventory $330.0K $276.4K
Prepaid Expenses
Receivables $255.5K $682.7K
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.127M $12.24M
YoY Change -59.25% 32.07%
LONG-TERM ASSETS
Property, Plant & Equipment $838.3K $1.168M
YoY Change -62.29% -54.33%
Goodwill
YoY Change
Intangibles $2.699M
YoY Change
Long-Term Investments
YoY Change
Other Assets $750.0K $1.026M
YoY Change 657.58% 979.94%
Total Long-Term Assets $5.525M $3.549M
YoY Change 137.94% 33.81%
TOTAL ASSETS
Total Short-Term Assets $8.127M $12.24M
Total Long-Term Assets $5.525M $3.549M
Total Assets $13.65M $15.79M
YoY Change -38.69% 32.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.072M $1.052M
YoY Change -38.53% -42.89%
Accrued Expenses $1.697M $1.564M
YoY Change -9.63% -7.23%
Deferred Revenue $76.44K $275.9K
YoY Change -86.44% -63.57%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.845M $2.891M
YoY Change -32.01% -32.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.250M $5.704M
YoY Change 1.52% 578.13%
Total Long-Term Liabilities $5.250M $5.704M
YoY Change 1.52% 578.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.845M $2.891M
Total Long-Term Liabilities $5.250M $5.704M
Total Liabilities $8.779M $8.595M
YoY Change -6.17% 67.7%
SHAREHOLDERS EQUITY
Retained Earnings -$302.4M -$298.9M
YoY Change 3.4% 2.4%
Common Stock $307.4M $306.1M
YoY Change 0.65% 2.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.951M $7.249M
YoY Change
Total Liabilities & Shareholders Equity $13.65M $15.79M
YoY Change -38.69% 32.46%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.592M -$3.100M
YoY Change 441.64% 175.73%
Depreciation, Depletion And Amortization $332.2K $349.1K
YoY Change 1.39% 8.71%
Cash From Operating Activities -$2.678M -$1.369M
YoY Change -17.83% -21.95%
INVESTING ACTIVITIES
Capital Expenditures $1.061M $24.20K
YoY Change -537.16% -131.56%
Acquisitions
YoY Change
Other Investing Activities $135.0K -$137.6K
YoY Change
Cash From Investing Activities -$925.8K -$161.8K
YoY Change 281.53% 111.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.678M -1.369M
Cash From Investing Activities -925.8K -161.8K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -3.603M -1.531M
YoY Change -134.21% -16.38%
FREE CASH FLOW
Cash From Operating Activities -$2.678M -$1.369M
Capital Expenditures $1.061M $24.20K
Free Cash Flow -$3.738M -$1.393M
YoY Change 23.96% -16.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9777199
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3303106
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12908520
dei Entity Central Index Key
EntityCentralIndexKey
0000744452
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 apdn Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q2 apdn Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q2 apdn Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36745
dei Entity Registrant Name
EntityRegistrantName
Applied DNA Sciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-2262718
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Health Sciences Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Stony Brook
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11790
dei City Area Code
CityAreaCode
631
dei Local Phone Number
LocalPhoneNumber
240-8800
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
APDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13658520
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10756235
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15215285
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
75000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
330853
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
682701
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3067544
CY2023Q2 us-gaap Inventory Net
InventoryNet
276422
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
524904
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1058056
CY2023Q2 us-gaap Assets Current
AssetsCurrent
12240262
CY2022Q3 us-gaap Assets Current
AssetsCurrent
19943129
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1168038
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2222988
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q2 apdn Capitalized Transaction Costs For Asset Purchase Transaction
CapitalizedTransactionCostsForAssetPurchaseTransaction
275726
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1355508
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
98997
CY2023Q2 us-gaap Assets
Assets
15789534
CY2022Q3 us-gaap Assets
Assets
22265114
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2127908
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487425
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
275885
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
563557
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2891218
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4185308
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
31467
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
868081
CY2023Q2 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
4804700
CY2022Q3 apdn Common Warrant Liability Noncurrent
CommonWarrantLiabilityNoncurrent
5139400
CY2023Q2 us-gaap Liabilities
Liabilities
8595466
CY2022Q3 us-gaap Liabilities
Liabilities
9356175
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12908520
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12909
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12909
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
306091402
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
305399008
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298854883
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292500088
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7249428
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12911829
CY2023Q2 us-gaap Minority Interest
MinorityInterest
-55360
CY2022Q3 us-gaap Minority Interest
MinorityInterest
-2890
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7194068
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15789534
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22265114
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4296371
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14609360
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1648023
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
3257113
us-gaap Cost Of Revenue
CostOfRevenue
7133271
us-gaap Cost Of Revenue
CostOfRevenue
9972479
CY2023Q2 us-gaap Gross Profit
GrossProfit
1269318
CY2022Q2 us-gaap Gross Profit
GrossProfit
1039258
us-gaap Gross Profit
GrossProfit
5454436
us-gaap Gross Profit
GrossProfit
4636881
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3292304
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3032877
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9440734
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11341176
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
836123
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
863025
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2796171
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3013162
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4128427
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3895902
us-gaap Operating Expenses
OperatingExpenses
12236905
us-gaap Operating Expenses
OperatingExpenses
14354338
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2859109
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2856644
us-gaap Operating Income Loss
OperatingIncomeLoss
-6782469
us-gaap Operating Income Loss
OperatingIncomeLoss
-9717457
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
26783
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34108
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5813
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
278400
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1758200
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-334700
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2540700
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3469
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26352
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6396
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43226
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3114195
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1124796
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6407265
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7605505
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3114195
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1124796
us-gaap Profit Loss
ProfitLoss
-6407265
us-gaap Profit Loss
ProfitLoss
-7605505
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14429
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-576
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-52470
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-833
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3099766
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1124220
us-gaap Net Income Loss
NetIncomeLoss
-6354795
us-gaap Net Income Loss
NetIncomeLoss
-7604672
apdn Deemed Dividend Related To Warrant Modifications
DeemedDividendRelatedToWarrantModifications
110105
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3099766
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1124220
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6354795
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7714777
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8982520
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8982520
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12908520
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12908520
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8184807
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8184807
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11112946
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1699920
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
300000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-4720911
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8391955
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272915
CY2022Q1 apdn Shares Issued In Public Offering
SharesIssuedInPublicOffering
-4091833
CY2022Q1 apdn Warrants Issued During Period Value Warrants
WarrantsIssuedDuringPeriodValueWarrants
-3350400
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1759797
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7646506
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272914
CY2022Q2 apdn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
74
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1124796
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6794698
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12908939
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93748
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3844246
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9158441
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
258604
CY2023Q1 us-gaap Profit Loss
ProfitLoss
551176
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9968221
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
340042
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-3114195
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
7194068
us-gaap Profit Loss
ProfitLoss
-6407265
us-gaap Profit Loss
ProfitLoss
-7605505
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1032568
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
962800
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6083
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-334700
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2540700
us-gaap Share Based Compensation
ShareBasedCompensation
692394
us-gaap Share Based Compensation
ShareBasedCompensation
2245749
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-255853
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000
apdn Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
62000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2640694
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
64928
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-325822
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-815294
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-632149
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
603439
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1631965
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
287672
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2113
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
345480
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
586379
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
-287672
apdn Increase Decrease In Deferred Revenues
IncreaseDecreaseInDeferredRevenues
476264
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3537911
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5718086
apdn Capitalized Transaction Costs For Asset Purchase Transaction Investing Activities
CapitalizedTransactionCostsForAssetPurchaseTransactionInvestingActivities
137604
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78535
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
246892
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171139
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-246892
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
75
apdn Net Proceeds From Sale Of Common Stock And Warrants
NetProceedsFromSaleOfCommonStockAndWarrants
4091833
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4091908
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3709050
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1873070
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15215285
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6554948
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11506235
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4681878
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
apdn Property Plant And Equipment Acquired And Included In Accounts Payable
PropertyPlantAndEquipmentAcquiredAndIncludedInAccountsPayable
249468
apdn Deemed Dividend Warrant Modifications
DeemedDividendWarrantModifications
110105
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
apdn Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
3350400
apdn Transaction Costs For Asset Purchase Included In Accounts Payable
TransactionCostsForAssetPurchaseIncludedInAccountsPayable
138122
apdn Issuance Of Stock Options Issued For Payment Of Accrued Bonus
IssuanceOfStockOptionsIssuedForPaymentOfAccruedBonus
300000
apdn Number Of Primary Markets That Use Company S Technologies
NumberOfPrimaryMarketsThatUseCompanySTechnologies
3
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
26425
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298854883
us-gaap Profit Loss
ProfitLoss
-6407265
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3537911
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates include revenue recognition, recoverability of long-lived assets, including the values assigned to property and equipment, fair value calculations for warrants, contingencies, and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p>
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4296371
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14609360
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9777199
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3303106
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10756235
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4681878
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
750000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11506235
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4681878
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, restricted cash and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. As of June 30, 2023, the Company had cash and cash equivalents of approximately $8.5 million in excess of the FDIC insurance limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2023 included an aggregate of 71% and 81%, respectively from two customers within the MDx Testing Services segment. 53% and 69% of the revenues earned for the three and nine-month periods ended June 30, 2023, respectively were derived from the COVID-19 testing contract with CUNY that terminated during June 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One customer from within the MDx Testing Services segment accounted for 64% and 55%, respectively, of the Company’s revenues earned from sale of products and services for the three and nine-month periods ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Two customers accounted for 86% of the Company’s accounts receivable at June 30, 2023 and two customers accounted for 89% of the Company’s accounts receivable at September 30, 2022.</p>
CY2023Q2 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
8500000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q2 apdn Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
212965
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
471947
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
55817
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
37032
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
74480
CY2023Q2 us-gaap Inventory Net
InventoryNet
276422
CY2022Q3 us-gaap Inventory Net
InventoryNet
602244
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1051723
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1744105
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
999952
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1458661
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
76233
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
418985
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2127908
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3621751
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7313963
CY2022Q3 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.68
apdn Class Of Warrant Or Right Forfeitures And Expirations
ClassOfWarrantOrRightForfeituresAndExpirations
18375
apdn Weighted Average Price Per Share Warrant Cancelled Or Expired
WeightedAveragePricePerShareWarrantCancelledOrExpired
17.60
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7295588
CY2023Q2 apdn Weighted Average Price Per Share Warrant Outstanding
WeightedAveragePricePerShareWarrantOutstanding
3.65
CY2013Q2 apdn Area Of Property Under Operating Lease
AreaOfPropertyUnderOperatingLease
30000
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2023Q1 apdn Area Of Laboratory Space
AreaOfLaboratorySpace
2500
CY2017Q4 apdn Lease For Satellite Testing
LeaseForSatelliteTesting
1108
CY2017Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12587707
CY2017Q4 apdn Base Rent During Initial Lease Term
BaseRentDuringInitialLeaseTerm
6500
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
174399
us-gaap Operating Lease Expense
OperatingLeaseExpense
489096
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
244306
us-gaap Operating Lease Cost
OperatingLeaseCost
342028
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
43750
us-gaap Short Term Lease Cost
ShortTermLeaseCost
260725
CY2023Q2 us-gaap Lease Cost
LeaseCost
288056
us-gaap Lease Cost
LeaseCost
602753
us-gaap Operating Lease Payments
OperatingLeasePayments
244306
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1545916
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.091
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
146584
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
586334
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
586334
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
195445
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1514697
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
159189
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1355508
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2917341
CY2023Q2 us-gaap Gross Profit
GrossProfit
1269318
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4296371
CY2022Q2 us-gaap Gross Profit
GrossProfit
1039258
us-gaap Gross Profit
GrossProfit
5454436
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14609360
us-gaap Gross Profit
GrossProfit
4636881
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
26783
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
278400
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1758200
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3469
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26352
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3114195
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1124796
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34108
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5813
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-334700
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2540700
apdn Transaction Cost Allocated To Warrant Liabilities
TransactionCostAllocatedToWarrantLiabilities
-391335
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6396
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43226
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6407265
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7605505
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4526300
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-278400
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4804700
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5139400
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
334700
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4804700

Files In Submission

Name View Source Status
0001410578-23-001688-index-headers.html Edgar Link pending
0001410578-23-001688-index.html Edgar Link pending
0001410578-23-001688.txt Edgar Link pending
0001410578-23-001688-xbrl.zip Edgar Link pending
apdn-20230630.xsd Edgar Link pending
apdn-20230630x10q.htm Edgar Link pending
apdn-20230630xex31d1.htm Edgar Link pending
apdn-20230630xex31d2.htm Edgar Link pending
apdn-20230630xex32d1.htm Edgar Link pending
apdn-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
apdn-20230630_cal.xml Edgar Link unprocessable
apdn-20230630_def.xml Edgar Link unprocessable
apdn-20230630_lab.xml Edgar Link unprocessable
apdn-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apdn-20230630x10q_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending